// App-Quantinova.ai

: Single-Cell Transcriptomic Analysis Reveals Reduction of Cytotoxic NK Cells in a Subset of Newly Diagnosed Multiple Myeloma Patients Impacting Outcome after Daratumumab Therapy

Researchers

Presenter

  • Sabrin Tahri

Principal Investigators

  • Madelon M.E. de Jong

  • Cathelijne Fokkema

  • Natalie Papazian

  • Zoltan Kellermayer

  • Michael Vermeulen

  • Mark van Duin

  • Pieter van de Woestijne

  • Kazem Nasserinejad

  • Elona Saraci

  • Mattia D'agostino

  • Francesca Gay

  • Vincent H.J. van der Velden

  • Niels WCJ van de Donk

  • Annemiek Broijl

  • Pieter Sonneveld

  • Sonja Zweegman

  • Tom Cupedo

Medical Centers

  • Department of Thoracic Surgery, Erasmus MC, Rotterdam, Netherlands

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston

  • Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands

  • Department of Hematology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, Netherlands

  • Erasmus University Medical Center Cancer Institute, Rotterdam, Netherlands

  • Erasmus MC Cancer Institute, Rotterdam, Netherlands

  • Erasmus MC Cancer Institute, department of Hematology, Rotterdam, Netherlands

  • Department of Hematology, Cancer Center Amsterdam, Amsterdam, Netherlands

  • Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands

  • Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy

Locations

  • Netherlands

  • United States

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • Solid malignancies

Biomarkers

  • Natural Killer cells

Drug/Treatment

  • daratumumab Intravenous

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved